Islet Sciences Signs Cell Therapy Alliance and Service Agreement With Progenitor Cell Therapy

Published: Jan 12, 2012

NEW YORK, Jan. 12, 2012 (GLOBE NEWSWIRE) -- Islet Sciences, Inc., a wholly-owned subsidiary of One E-Commerce Corporation (OTCBB:ONCE) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that the company has signed a services agreement with Progenitor Cell Therapy (PCT), a wholly owned subsidiary of NeoStem Inc. (NYSE Amex:NBS), and a leader in providing custom-tailored cell therapy services.

Back to news